ANI Pharmaceuticals reports Q2 profit of $24.71M, up 202%

ANI Pharmaceuticals, Inc. reported its second‑quarter earnings on Tuesday, showing a sharp rise in profit and revenue compared with the same period last year. Net income climbed to $24.71 million, or $1.05 per share, versus $8.14 million, $0.36 per share a year earlier. Adjusted earnings—excluding one‑time items—reached $47.63 million, or $2.21 per share, reflecting a stronger core business.

The company’s revenue increased 25.9 percent to $266.04 million, up from $211.37 million in Q2 2023. The jump comes as ANI has expanded its product line and secured new distribution agreements. Analysts note that the growth is driven largely by higher sales of its flagship drug, which has seen rising demand in specialty markets. The company’s earnings per share beat consensus estimates by a comfortable margin, sparking a positive reaction from investors.

Looking ahead, ANI provided guidance for the full year. Management expects earnings per share between $9.19 and $9.69, and total revenue between $1.080 billion and $1.140 billion. These forecasts suggest the company plans to maintain its growth trajectory and invest in research and development. The guidance also indicates a continued focus on expanding its market share in key therapeutic areas. Investors will be watching how the company translates its Q2 momentum into long‑term performance, especially as it navigates regulatory and competitive pressures.